July 13, 2023: MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Date : July 13, 2023

MaaT Pharma: Half-year Report on Liquidity Contract With the Brokerage Firm Kepler Cheuvreux

Lyon, France, July 13, 2023 6:00 pm CET – MaaT Pharma (EURONEXT: MAAT – the “Company”), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem TherapiesTM (MET) dedicated to improving survival outcomes for patients with cancer, today announces its half-year report on the liquidity contract with the brokerage firm Kepler Cheuvreux.

Under the liquidity contract entered on June 30th, 2023, between Maat Pharma and Kepler Cheuvreux, the following resources appeared on the liquidity account:

    • 15,484 shares
    • € 41,285.13
    • Number of executions on buy side on semester: 552
    • Number of executions on sell side on semester: 431
    • Traded volume on buy side on semester: 15,974 shares for € 144,745.75
    • Traded volume on sell side on semester: 12,997 shares for € 122,384.16

As a reminder:

  • the following resources appeared on the last half year statement on December 31st, 2022, on the liquidity account:
    • 12,507 shares
    • € 63,045.61
    • Number of executions on buy side on semester: 390
    • Number of executions on sell side on semester: 330
    • Traded volume on buy side on semester: 14,188 shares for € 131,237.39
    • Traded volume on sell side on semester: 9,342 shares for € 86,141.8

 

  • the following resources appeared on the liquidity account when the activity started:
    • 0 shares
    • € 200,000.00

The implementation of this report is carried out in accordance with AMF Decision N°2021-01 of June 22nd, 2021, renewing the implementation of liquidity contracts for shares as an accepted market practice.

 

Buy side Sell side
Number of executions Number of shares Traded volume in EUR Number of executions Number of shares Traded volume in EUR
Total 552 15,974 144,745.75 431 12,997 122,384.16
02/01/2023 1 1 8.02 4 67 539.35
03/01/2023 1 5 40.00 2 20 161.60
04/01/2023 14 460 3,910.00
05/01/2023 9 281 2,554.29 14 493 4,757.45
06/01/2023 4 88 796.40
09/01/2023 5 261 2,268.09
10/01/2023 2 41 348.50 1 1 8.62
11/01/2023 6 139 1,167.60 2 49 416.50
12/01/2023 8 222 1,847.04
13/01/2023 8 220 1,867.80
16/01/2023 8 200 1,726.00 5 150 1,326.00
17/01/2023 2 60 519.00 2 41 360.80
18/01/2023 2 70 602.00 1 40 348.00
19/01/2023 4 59 522.15
20/01/2023 4 130 1,140.10 4 250 2,250.00
23/01/2023 2 50 424.00 1 30 258.00
24/01/2023 1 1 8.62 4 62 543.74
25/01/2023 5 185 1,650.20 15 499 4,525.93
26/01/2023 4 71 641.13 6 201 1,839.15
27/01/2023 3 60 546.00 2 63 580.86
30/01/2023 1 50 460.00 5 67 623.10
31/01/2023 2 51 464.10 2 51 469.20
01/02/2023 3 101 924.15 4 51 472.26
02/02/2023 4 185 1,652.05 7 300 2,703.00
03/02/2023 21 596 5,673.92
06/02/2023 13 502 4,663.58 4 150 1,440.00
07/02/2023 4 174 1,599.06 1 50 467.00
08/02/2023 20 654 5,886.00 7 300 2,814.00
09/02/2023 8 330 2,880.90 6 152 1,377.12
10/02/2023 5 202 1,801.84 4 140 1,261.40
13/02/2023 7 353 3,014.62 5 180 1,562.40
14/02/2023 3 110 957.00 5 131 1,151.49
15/02/2023 4 112 976.64 3 80 707.20
16/02/2023 3 90 812.70 9 311 2,839.43
17/02/2023 5 61 559.98 1 50 460.00
20/02/2023 3 98 909.44 6 199 1,864.63
21/02/2023 3 73 675.98 3 51 474.30
22/02/2023 4 63 598.50 16 689 6,724.64
23/02/2023 7 144 1,368.00 5 155 1,488.00
24/02/2023 7 215 2,126.35 13 510 5,120.40
27/02/2023 4 100 1,005.00
28/02/2023 3 105 1,033.20 2 106 1,061.06
01/03/2023 4 120 1,207.20 16 1 071 11,288.34
02/03/2023 6 105 1,121.40
03/03/2023 16 450 4,846.50 8 350 3,853.50
06/03/2023 5 184 1,928.32 4 148 1,567.32
07/03/2023 5 76 801.04 4 121 1,291.07
08/03/2023 4 94 1,000.16 3 41 442.80
09/03/2023 17 583 5,853.32 3 30 303.00
10/03/2023 3 60 595.80
13/03/2023 20 730 6,942.30 1 60 576.00
14/03/2023 6 80 765.60 5 160 1,556.80
15/03/2023 6 151 1,449.60 1 1 9.72
16/03/2023 3 51 484.50 3 41 393.60
17/03/2023 5 150 1,438.50 3 64 627.20
20/03/2023 1 40 376.00 1 40 380.00
21/03/2023 4 41 389.50 1 1 9.58
22/03/2023 1 26 247.00 4 146 1,416.20
23/03/2023 2 50 489.00 2 39 384.93
24/03/2023 20 495 4,653.00 4 77 730.73
27/03/2023 14 306 2,836.62 12 369 3,516.57
28/03/2023 3 95 949.05 13 365 3,719.35
29/03/2023 12 330 3,313.20 3 60 621.00
30/03/2023 3 36 355.32 3 70 697.20
31/03/2023 2 51 510.00 6 200 2,054.00
03/04/2023 1 18 180.00
04/04/2023 5 83 830.00 2 6 60.54
05/04/2023 2 70 700.00 1 12 121.20
06/04/2023 2 51 510.00 3 11 111.10
11/04/2023 5 50 500.00
12/04/2023 9 158 1,537.34 3 90 887.40
13/04/2023 7 90 894.60
14/04/2023 7 210 2,037.00 2 50 490.00
17/04/2023 13 375 3,562.50 2 65 624.00
18/04/2023 3 120 1,138.80 3 32 304.32
19/04/2023 2 80 752.00 3 49 465.50
21/04/2023 2 20 190.00
24/04/2023 6 243 2,340.09 10 339 3,328.98
25/04/2023 3 100 977.00 4 160 1,580.80
26/04/2023 1 1 9.72 1 1 9.72
27/04/2023 4 110 1,052.70
28/04/2023 16 528 4,778.40 4 170 1,558.90
02/05/2023 3 50 454.00
03/05/2023 1 1 9.08 1 1 9.08
04/05/2023 9 230 2,017.10 4 19 167.39
05/05/2023 7 92 821.56
08/05/2023 7 146 1,278.96 1 1 8.92
09/05/2023 3 60 522.00 3 50 440.00
10/05/2023 6 214 1,821.14 2 50 440.00
11/05/2023 8 156 1,285.44 3 87 727.32
12/05/2023 1 1 8.28 4 84 709.80
15/05/2023 4 131 1,074.20 4 170 1,434.80
16/05/2023 3 110 936.10 4 100 865.00
17/05/2023 1 40 332.00
19/05/2023 6 354 2,842.62
22/05/2023 1 50 400.00
23/05/2023 5 40 320.00
24/05/2023 1 1 7.98 3 41 328.00
25/05/2023 3 50 400.00
29/05/2023 5 101 828.20
30/05/2023 2 31 251.10 1 1 8.20
31/05/2023 1 50 400.00
01/06/2023 1 1 7.98 1 1 7.98
05/06/2023 2 30 240.00 1 30 243.00
06/06/2023 3 170 1,353.20 1 1 8.20
07/06/2023 3 151 1,182.33 1 1 7.90
08/06/2023 3 91 715.26 1 1 7.90
09/06/2023 4 91 707.07 2 51 402.90
12/06/2023 6 256 1,966.08 3 64 493.44
13/06/2023 2 80 616.00 4 112 873.60
14/06/2023 4 116 886.24 4 67 513.22
15/06/2023 3 140 1,045.80 1 27 202.50
16/06/2023 1 3 22.50 4 80 608.00
19/06/2023 8 282 2,092.44 3 160 1,214.40
21/06/2023 2 60 448.20
22/06/2023 2 70 520.80
23/06/2023 4 101 737.30 3 61 457.50
26/06/2023 1 1 7.28 1 1 7.28
27/06/2023 1 20 148.00
28/06/2023 5 194 1,402.62
29/06/2023 4 203 1,467.69
30/06/2023 1 30 216.00

About MaaT Pharma

MaaT Pharma, a clinical stage biotechnology company, has established a complete approach to restoring patient-microbiome symbiosis in oncology. Committed to treating cancer and graft-versus-host disease (GvHD), a serious complication of allogeneic stem cell transplantation, MaaT Pharma has launched, in March 2022, an open-label, single arm Phase 3 clinical trial in patients with acute GvHD, following the achievement of its proof of concept in a Phase 2 trial. Its powerful discovery and analysis platform, gutPrint®, enables the identification of novel disease targets, evaluation of drug candidates, and identification of biomarkers for microbiome-related conditions. The company’s Microbiome Ecosystem Therapies are produced through a standardized cGMP manufacturing and quality control process to safely deliver the full diversity of the microbiome, in liquid and oral formulations. MaaT Pharma benefits from the commitment of world-leading scientists and established relationships with regulators to support the integration of the use of microbiome therapies in clinical practice. MaaT Pharma is listed on Euronext Paris (ticker: MAAT).

[maat_prev_next_nav]

Acting Chief Scientific Officer

Sheri Simmons

Sheri Simmons, Ph.D., is Acting Chief Scientific Officer at MaaT Pharma. Sheri brings extensive experience in biotechnology, particularly in the microbiome field, having held scientific leadership positions at Seres Therapeutics, Johnson & Johnson’s Microbiome Solutions team, and most recently at Seed Health, a leading probiotics company. In her role, she strengthens the Company’s scientific leadership, overseeing preclinical research, AI/data initiatives, and supporting efforts toward the Marketing Authorization Application of Xervyteg® in aGvHD.

Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences. Sheri holds a PhD in Biological Oceanography from the Massachusetts Institute of Technology (MIT) and completed an A.B. in Ecology & Evolutionary Biology at Princeton University, graduating summa cum laude and as a Phi Beta Kappa member, receiving one of six awards for the best senior thesis in the sciences.

CEO and co-founder

Hervé Affagard

Hervé Affagard is the CEO and co-founder of MaaT Pharma. For the past 15 years, Hervé has been an intra/entrepreneur in the healthcare industry, after starting his career in IT in the steel industry. In late 2014, Hervé co-founded the company alongside Dr. Joël Doré, author of nearly 500 publications, and
one of the world’s most cited authors in the microbiome sphere today, after a professional career that spanned multiple industries. Hervé has led MaaT Pharma’s development from its early concept in 2013 and has been at the forefront of the development of the microbiome healthcare ecosystem in France and Europe. In January 2022, Hervé has been elected President of Allliance Promotion Microbiote, an organization founded in 2021 to support the microbiome sector development in France.

Engineer, MBA